Patents by Inventor Scott Ronald BRODEUR
Scott Ronald BRODEUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124581Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: ApplicationFiled: September 1, 2023Publication date: April 18, 2024Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAAF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, Jr., Haiguang XIAO, Danlin YANG
-
Patent number: 11919962Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.Type: GrantFiled: April 16, 2021Date of Patent: March 5, 2024Assignee: Bristol Myers-Squibb CompanyInventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
-
Publication number: 20240059789Abstract: Provided herein, in certain aspects, are antibodies that bind to PSMA, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to PSMA and CD3, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.Type: ApplicationFiled: January 24, 2022Publication date: February 22, 2024Inventors: Theresa McDevitt, Danlin Dan Qing Yang, Sanjaya Singh, Scott Ronald Brodeur, Jennifer Hertzog
-
Patent number: 11795219Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 11, 2020Date of Patent: October 24, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
-
Publication number: 20230265203Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.Type: ApplicationFiled: October 7, 2022Publication date: August 24, 2023Applicant: Boehringer Ingelheim International GmbHInventors: Scott Ronald BRODEUR, Thomas B. FREEMAN, Gerald Henry Nabozny, Meera RAMANUJAM, Paul SCHOLL, Juergen STEFFGEN
-
Publication number: 20220267438Abstract: Provided herein are multispecific antibodies that bind to BCMA, GPRC5D and CD3 and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are antibodies that bind to BCMA and antigen-binding fragments thereof.Type: ApplicationFiled: February 15, 2022Publication date: August 25, 2022Inventors: Ricardo Marcos Attar, Scott Ronald Brodeur, Rajkumar Ganesan, Leopoldo Luistro, Ulrike Philippar, Kodandaram Pillarisetti, Sanjaya Singh, I, Danlin Dan Qing Yang
-
Patent number: 11370818Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: June 25, 2019Date of Patent: June 28, 2022Assignee: Boehringer Ingelheim International GmbHInventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
-
Publication number: 20220153857Abstract: The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: February 7, 2022Publication date: May 19, 2022Applicant: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca BARRETT, Scott Ronald BRODEUR, Keith CANADA, Tobias Litzenburger, Sanjaya Singh
-
Patent number: 11242394Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: July 10, 2018Date of Patent: February 8, 2022Assignee: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
-
Publication number: 20220017627Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.Type: ApplicationFiled: April 16, 2021Publication date: January 20, 2022Inventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
-
Patent number: 11028169Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 18, 2017Date of Patent: June 8, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
-
Patent number: 11008395Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.Type: GrantFiled: January 21, 2020Date of Patent: May 18, 2021Assignee: Bristol Myers-Squibb CompanyInventors: Aaron Paul Yamniuk, Scott Ronald Brodeur, Ekaterina Deyanova, Richard Yu-Cheng Huang, Yun Wang, Alfred Robert Langish, Guodong Chen, Stephen Michael Carl, Hong Shen, Achal Mukundrao Pashine, Lin Hui Su
-
Publication number: 20210095020Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: ApplicationFiled: May 11, 2020Publication date: April 1, 2021Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAFF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, JR., Haiguang XIAO, Danlin YANG
-
Publication number: 20200231687Abstract: Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7R?). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.Type: ApplicationFiled: January 21, 2020Publication date: July 23, 2020Applicant: Bristol Myers-Squibb CompanyInventors: Aaron Paul YAMNIUK, Scott Ronald BRODEUR, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Yun WANG, Alfred Robert LANGISH, Guodong CHEN, Stephen Michael CARL, Hong SHEN, Achal Mukundrao PASHINE, Lin Hui SU
-
Publication number: 20190309034Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: June 25, 2019Publication date: October 10, 2019Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
-
Patent number: 10377804Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: November 6, 2017Date of Patent: August 13, 2019Assignee: Boehringer Ingelheim International GmbHInventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
-
Publication number: 20190177420Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.Type: ApplicationFiled: July 18, 2018Publication date: June 13, 2019Applicant: Boehringer Ingelheim International GmbHInventors: Scott Ronald Brodeur, Thomas B. Freeman, Gerald Henery Nabozny, Meera Ramanujam, Paul Scholl, Juergen Steffgen
-
Publication number: 20190169301Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: July 10, 2018Publication date: June 6, 2019Applicant: Boehringer Ingelheim International GmbHInventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
-
Publication number: 20180127474Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: November 6, 2017Publication date: May 10, 2018Inventors: Scott Ronald BRODEUR, Keith A. CANADA, Michael DZIEGELEWSKI, Philip Nicholas GORMAN, Pankaj GUPTA, Ashraf KHALIL, John J. MIGLIETTA, Amy Marie NICOLETTI, Qi PAN, David PRESKY, Sanjaya SINGH, Tao WU, Haiguang XIAO
-
Patent number: 9840543Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: January 30, 2015Date of Patent: December 12, 2017Assignee: Boehringer Ingelheim International GmbHInventors: Scott Ronald Brodeur, Keith Canada, Mlchael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John James Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
